EARLY ACS
- 10,500 participants
- 4 sites in New Zealand
- 500 sites globally
Early Glycoprotein IIb/IIIa Inhibition in Non-ST-segment Elevation Acute Coronary Syndrome: A Randomised, Placebo-Controlled Trial Evaluating the Clinical Benefits of Early Front-loaded Eptifibatide in the Treatment of Patients with Non-ST-segment Elevation Acute Coronary Syndrome
This was a multi-national, randomised, placebo-controlled, double-blind, parallel-group trial evaluating the clinical benefits of early front-loaded Eptifibadite in treatment of participants with Non-ST-segment Elevation Acute Coronary Syndrome” NSTE ACS (significant heart pain or heart attack) who were planned to undergo an invasive strategy no sooner than the next calendar day following randomisation. In New Zealand, this study was conducted as Phase IV study as eptifibatide is a registered drug.